$8.52
-0.22-2.52%
Last update: Oct 30, 9:29 AM
ImmunityBio Inc (IBRX) Stock Price, Quote, News & History
IBRXNASDAQ
ImmunityBio (IBRX) stock jumps over 5% following FDA expanded approval for Anktiva in NMIBC bladder cancer treatment. Get details.
You can purchase shares of ImmunityBio (NASDAQ:IBRX) through any online brokerage.
Other companies in ImmunityBio’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
ImmunityBio has a consensus price target of $15.25.
The stock price for ImmunityBio (NASDAQ: IBRX) is $8.52 last updated October 30, 2026 at 9:29 AM EDT.
There are no upcoming dividends for ImmunityBio.
ImmunityBio does not have any upcoming earnings scheduled.
There is no upcoming split for ImmunityBio.
ImmunityBio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach...
